Stammdaten

Register
Amtsgericht Charlottenburg (Berlin) HRB 201569
Eingetragen
22.11.2018
Branche
Managementtätigkeiten von sonstigen HoldinggesellschaftenBeteiligungsgesellschaftenManagementtätigkeiten von Holdinggesellschaften mit überwiegend finanziellem Anteilsbesitz
Gegenstand
Der Erwerb, das Halten und Verwalten von Beteiligungsgesellschaften und deren unternehmerische Steuerung sowie die Erbringung von erlaubnisfreien Beratungs- und Managementdienstleistungen, jeweils insbesondere im Gesundheitsbereich.

Finanzübersicht

Historie

Keine Bekanntmachungen für diesen Filter verfügbar

Management

NameRolle
Christian Gaul
seit 18.11.2025
Prokura
Dipesh Mahtani
seit 18.11.2025
Geschäftsführer
Prokura
Stephan Kaune
seit 18.11.2025
Geschäftsführer
Prokura
Riccardo Pariti
seit 18.11.2025
Geschäftsführer
Prokura
Geschäftsführer

Wirtschaftlich Berechtigte
Beta

0.00% identifiziert100.00% ungelöst

Ungelöste Beteiligungen (1)

NameAnteil
Sanoptis S.à r.l.LUX
100.00%

Gesellschafter
Beta

Name
Ort
Anteil
Sanoptis Sarl
Luxembourg
100.00%

Beteiligungen
Beta

NameAnteil
No data available

Konzern- und Jahresabschlüsse

Sanoptis S.à.r.l.

Luxemburg

Konzernabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021

Consolidated accounts of the Sanoptis Group 31 st December 2021

TABLE OF CONTENTS

REPORT OF THE RÉVISEUR D'ENTREPRISES AGRÉÉ

CONSOLIDATED ACCOUNTS

- Consolidated balance sheet as of 31 December 2021

- Consolidated profit and loss account

- Notes to the consolidated accounts

REPORT OF THE RÉVISEUR D'ENTREPRISES AGRÉÉ

Report on the audit of the consolidated accounts

Opinion

We have audited the consolidated accounts of Sanoptis S.à r.l. and its subsidiaries (the "Group"), which comprise the consolidated balance sheet as at 31 December 2021, and the consolidated profit and loss account for the year then ended, and notes to the consolidated accounts, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated accounts give a true and fair view of the consolidated financial position of the Group as at 31 December 2021 and of the consolidated results of its operations for the year then ended in accordance with Luxembourg legal and regulatory requirements relating to the preparation and presentation of the consolidated accounts.

Basis for opinion

We conducted our audit in accordance with the Law of 23 July 2016 on the audit profession ("Law of 23 July 2016") and with International Standards on Auditing ("ISAs") as adopted for Luxembourg by the Commission de Surveillance du Secteur Financier ("CSSF"). Our responsibilities under the Law of 23 July 2016 and ISAs as adopted for Luxembourg by the CSSF are further described in the « Responsibilities of "réviseur d'entreprises agréé" for the audit of the consolidated accounts » section of our report. We are also independent of the Group in accordance with the International Code of Ethics for Professional Accountants, including International Independence Standards, issued by the International Ethics Standards Board for Accountants ("IESBA Code") as adopted for Luxembourg by the CSSF together with the ethical requirements that are relevant to our audit of the consolidated accounts, and have fulfilled our other ethical responsibilities under those ethical requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

The Board of Managers is responsible for the other information. The other information comprises the information stated in the consolidated report including the consolidated management report but does not include the consolidated accounts and our report of the "réviseur d'entreprises agréé" thereon.

Our opinion on the consolidated accounts does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated accounts, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated accounts or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report this fact. We have nothing to report in this regard.

Responsibilities of the Board of Managers for the consolidated accounts

The Board of Managers is responsible for the preparation and fair presentation of the consolidated accounts in accordance with Luxembourg legal and regulatory requirements relating to the preparation and presentation of the consolidated accounts, and for such internal control as the Board of Managers determines is necessary to enable the preparation of consolidated accounts that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated accounts, the Board of Managers is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Managers either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Responsibilities of the réviseur d'entreprises agréé for the audit of the consolidated accounts

The objectives of our audit are to obtain reasonable assurance about whether the consolidated accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue a report of the "réviseur d'entreprises agréé" that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Law of 23 July 2016 and with ISAs as adopted for Luxembourg by the CSSF will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated accounts.

As part of an audit in accordance with the Law of 23 July 2016 and with ISAs as adopted for Luxembourg by the CSSF, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the consolidated accounts, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Managers.

Conclude on the appropriateness of the Board of Managers' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our report of the "réviseur d'entreprises agréé" to the related disclosures in the consolidated accounts or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our report of the "réviseur d'entreprises agréé". However, future events or conditions may cause the Group to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the consolidated accounts, including the disclosures, and whether the consolidated accounts represent the underlying transactions and events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the financial information of the entities and business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the Group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on other legal and regulatory requirements

The consolidated management report is consistent with the consolidated accounts and has been prepared in accordance with applicable legal requirements.

 

Luxembourg, 22 June 2022

KPMG Luxembourg
Société anonyme
Cabinet de revision agréé

Yves Thorn

Consolidated balance sheet as of 31 December 2021

CONSOLIDATED BALANCE SHEET AS OF 31 DECEMBER 2021

ASSETS NOTE 31/12/2021 31/12/2020
A) FIXED ASSETS
I Intangible fixed assets: 4
2) Concessions, patents, licenses, trademarks and similar rights and assets, if they were 4
a) Acquired for valuable consideration and need not be shown under C.I.3 748.596,72 364.347,83
b) Created by the undertaking itself to the extent that national law permits activation 4.695,00
3) Goodwill to the extent that it was acquired for valuable consideration 390.643.229,48 272.239.571,94
391.396.521,20 272.603.919,77
II Tangible fixed assets: 5
1) Land and buildings 4.704.146,33 2.227.379,49
2) Plant and machinery 20.830.836,80 12.023.273,98
3) Other fixtures and fittings, tools and equipment 24.113.440,80 12.154.994,78
4) Payments on account and tangible fixed assets in the course of construction 1.640.660,76 943.548,80
51.289.084,69 27.349.197,05
III Financial fixed assets: 6
1) Shares in affiliated undertakings
3) Participating interest 96.139,51 40.123,58
5) Investments held as fixed assets 1.935,92 1.851,51
6) Loans to affiliated undertakings 429.474,55 206.931,76
527.549,98 248.906,85
B) TOTAL FIXED ASSETS 443.213.155,87 300.202.023,67
C) CURRENT ASSETS
I Stocks:
1) Raw materials and consumables 2.567.244,67 1.778.273,46
2) Work in progress 75.077,14 41.449,36
3) Finished goods and goods for resale 299.546,30 386,87
4) Payment on account - -
2.941.868,11 1.820.109,69
II Debtors:
1) Trade debtors
a) Becoming due and payable within one year 34.600.403,71 22.115.262,50
34.600.403,71 22.115.262,50
3) Amounts owed by undertakings with which the undertaking is linked by virtue of participating interests
a) Becoming due and payable within one year - 82.966,14
- 82.966,14
4) Other debtors
a) Becoming due and payable within one year 9.109.220.94 4.130.735,07
9.109.220.94 4.130.735,07
IV Cash at bank and in hand 63.756.507,03 23.809.454,26
D) TOTAL CURRENT ASSETS 110.407.999,79 51.958.527,66
E) PREPAYMENTS 1.196.075,41 850.153,06
F) DEFFERED TAX ASSET 54.951,76 62.370,84
TOTAL ASSETS 554.872.182,83 353.073.075,23
The notes in the annex form an integral part of the consolidated accounts.

CONSOLIDATED BALANCE SHEET AS OF 31 DECEMBER 2021

LIABILITIES NOTE 31/12/2021 31/12/2020
A) Capital and reserves 7
I Subscribed capital 27.293.600,00 27.293.600,00
II Share premium account 11.029.831,77 11.029.831,77
IV Reserves (217.097,60) 664.578,03
4. Other reserves, including the fair value reserve (217.097,60) 664.578,03
b) other non-available reserve (217.097,60) 664.578,03
V Profit or loss brought forward (33.442.143,36) (12.544.663,43)
VI Profit of loss for the financial year / period (39.113.972,75) (20.897.480,09)
VIII Capital investment subsidies 1.019.754,49 710.398,63
IX Minority interest 46.799.805.60 21.870.783.10
A) TOTAL CAPITAL AND RESERVES 13.369.778,15 28.127.048,00
B) PROVISIONS
3. Other provisions 10.258.460,89 848.188,95
TOTAL PROVISIONS 10.258.460,89 848.188,95
C) CREDITORS 8
2 Amounts owed to credit institutions:
a) becoming due and payable after less than one year 5.158.729,82 2.976.005,87
b) becoming due and payable after more than one year 375.465.963,67 200.184.306,12
203.160.311,99 380.624.693,49
3 Payments received on account of orders in so far as they are not shown separately as deductions from stocks
a) becoming due and payable after less than one year 60.587,54 -
60.587,54 -
4 Trade creditors:
a) becoming due and payable after less than one year 14.187.293,82 9.987.684,20
b) becoming due and payable after more than one year 6.453,83 -
6 Amount owed to affiliated undertakings: 14.193.747,65 9.987.684,20
a) becoming due and payable after less than one year 2.642.865,58 7.939.563,20
b) becoming due and payable after more than one year 94.111.339,24 90.040.390,23
96.754.204,82 97.979.953,43
8 Other creditors
c) Other creditors
i) becoming due and payable after less than one year 32.466.981,59 10.350.931,69
ii) becoming due and payable after more than one year 3.289.378,08 2.031.470,51
35.756.359,67 12.382.402,20
TOTAL CREDITORS 527.389.593,17 323.510.351,82
E) DEFERRED TAX LIABILITIES 3.698.499,22 577.534,59
D) DEFERRED INCOME 155.851,40 9.951,86
TOTAL (CAPITAL, RESERVES AND LIABILITIES) 554.872.182,83 353.073.075,22

The notes in the annex form an integral part of the consolidated accounts.

Consolidated profit and loss account

CONSOLIDATED PROFIT AND LOSS ACCOUNT
NOTE 31/12/2021 31/12/2020
1) Net turnover 9 222.125.954,06 134.598.932,65
2) Variation in stocks of finished goods and in work in progress - -
4) Other operating income 5.102.537,46 2.632.013,99
5) Raw materials and consumables and other external expenses 10 (83.970.191,83) (50.520.988,44)
a) Raw materials and consumables (39.836.254,43) (25.259.931,71)
b) Other external charges (44.133.937,40) (25.261.056,73)
6) Staff costs 11 (93.507.898,54) (57.077.515,63)
a) Salaries and wages (80.966.405,56) (49.530.851,42)
b) Social security costs (12.541.492,98) (7.546.664,21)
7) Value adjustments (57.121.786,60) (30.975.284,19)
a) in respect of formation expenses and tangible and intangible fixed assets 4 , 5 (57.121.786,60) (30.975.284,19)
b) in respect of current assets - -
8) Other operating expenses (2.672.737,45) (1.543.726,58)
10) Income from other investments and loans forming part of the fixed assets 984.278,07 585,83
a) derived from affiliated undertakings 984.278,07
b) other income not included in a) - 585,83
13) Value adjustments in respect of financial assets and of investments held as current asset (50.597,11) -
14) Interest payable and similar expenses (21.557.124,42) (14.910.675,39)
a) concerning affiliated undertakings (4.340.919,39) (5.836.513,00)
b) other interest and similar expenses (17.216.205,03) (9.074.162,39)
15) Tax on profit or loss 12 (7.449.038,24) (1.441.582,89)
16) Profit or loss after taxation (38.116.604,60) (19.238.240,65)
17) Other taxes not shown under items 1 to 16 (49.399,20) (80.182,90)
18) Profit or loss for the financial period (38.166.003,80) (19.318.423,55)
19) Profit attributable to minority interest (947.968,95) (1.579.056,54)
20) Total Profit or loss for the financial period for the group (39.113.972,75) (20.897.480,09)

The notes in the annex form an integral part of the consolidated accounts.

Notes to the consolidated accounts

NOTE 1 - GENERAL INFORMATION

Sanoptis S.à r.l. ("the Company"; the "Parent") was incorporated as a Société à responsabilité limitée under the laws of the Grand Duchy of Luxembourg on 24 September 2018 for an unlimited period.

The main purposes of the Company are the holding of participations in companies in the Grand Duchy of Luxembourg and in foreign companies and the provision of financing to companies of the same group.

The first financial year began on 24 September 2018 (date of incorporation) and ended on 31 December 2019. The following financial years will start on 1 January and end on 31 December.

At the date of incorporation of the Company, its registered office was established at 6C, rue Gabriel Lippmann, L-5365 Munsbach, and the Company is registered with the Register of Commerce of Luxembourg under section B number 228211. On 1 October 2020, the Company moved its registered office from 6C, rue Gabriel Lippmann, L-5365 Munsbach to 53, Boulevard Royal, L-2449 Luxembourg.

The purpose of the Company with its subsidiaries (the "Group"), is an innovative ophthalmological network with medical operations in Germany and Switzerland. Sanoptis S.à r.l., the Company, was incorporated on 24 September 2018 by its sole shareholder at the time, Telemos Holding S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated under the laws of Luxembourg. All Group entities included in the scope of consolidation have a financial year ending on 31 December or prepared financial information for consolidation purposes on 31 December.

NOTE 2 - BASIS FOR PREPARATION, SCOPE OF CONSOLIDATION AND CONSOLIDATION POLICIES

2.1 Basis of presentation

The consolidated accounts of the Company have been prepared in accordance with Luxembourg legal and regulatory requirements under the historical cost convention.

The consolidated accounts are prepared in accordance with the provisions of the law of 10 August 1915 on Commercial Companies. In relation to the accounting policies and valuation rules the latter is supplemented by the provisions as laid down by the Law of 19 December 2002 as amended or determined and applied by the Board of Managers.

2.2 Critical accounting estimates

The preparation of consolidated accounts of the Company requires the use of certain critical accounting estimates. It also requires the Board of Managers to exercise its judgement in the process of applying the accounting policies. Changes in assumptions may have a significant impact on the consolidated accounts of the Company in the period in which the assumptions changed. The Board of Managers believes that the underlying assumptions are appropriate and that the consolidated accounts of the Company therefore present the financial position and results fairly.

The Board of Managers makes estimates and assumptions that affect the reported amounts of assets and liabilities in the next financial year. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The consolidated accounts have been prepared in accordance with Luxembourg legal and regulatory requirements as defined below.

2.3 Impacts from COVID, Conflict Russia and Ukraine and Going Concern

Management has considered the impact of the Covid-19 pandemic and the conflict between Russia and Ukraine, both operationally and financially. They have also reviewed the projections and forecasts of the Group and have a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future and that no material uncertainty exists that cast doubt on the Company's ability to continue as a going concern. Accordingly, the Group continues to adopt the going concern basis in preparing its consolidated accounts.

2.4 Scope of consolidation

The consolidated accounts as at 31 December 2021 of the Company include its stand-alone annual accounts and those of all directly and indirectly majority owned subsidiaries. Subsidiaries are all entities over which the Company exercises control. Control is defined as the direct and indirect power to govern the financial and operating policies, so as to obtain benefits from its activities. The existence and effect of potential voting rights that are currently exercisable or convertible, including potential voting rights owned by other entities, are considered when assessing whether the group controls another entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are no longer consolidated from the date of loss of control.

The Group and the minority interests' share of profits or losses in the net equity of subsidiaries are determined based on existing voting rights, without considering the effects of potential voting rights which are exercisable or convertible.

Joint ventures are operations that are jointly controlled by the Group and one or more other parties in accordance with contractual arrangements between the parties. Those operations are consolidated using the proportional consolidation method or the equity method of accounting.

Associates are all entities over which the Group has significant influence, but not control, generally accompanying a shareholding of between 20% and 50% of the voting rights. Investments in associates are accounted for using the equity method of accounting. The Group's investment in associates includes goodwill identified on acquisition, net of any accumulated value adjustment.

Entities included in the scope of consolidation are listed below:

Consolidated subsidiaries per country Registered office Percentage of control Method of consolidation
1) Germany
Sanoptis GmbH Friedrichstrasse 95, Berlin, AG Charlottenburg HRB 201569 100% Full consolidation *)
Augenarztservice Braunschweig GmbH Wolfenbütteler Straße 82, 38102 Braunschweig, AG Braunschweig HRB 201413 100% Full consolidation *)
Augenklinik Dr. Hoffmann GmbH Wolfenbütteler Straße 82, 38102 Braunschweig, AG Braunschweig, HRB 207446 100% Full consolidation *)
Augenärzte Braunschweig-Göttingen MVZ GmbH Wolfenbütteler Straße 82, 38102 Braunschweig, AG Braunschweig HRB 207448 70% Full consolidation *)
nordBLICK Augenklinik Bellevue GmbH Lindenallee 21 - 23, 24105 Kiel, AG Kiel HRB 16549 KI 100% Full consolidation *)
nordBLICK MVZ GmbH Lindenallee 21 - 23, 24105 Kiel, AG Kiel HRB 17310 90% Full consolidation *)
Aalen MVZ GmbH Südlicher Stadtgraben 13, 73430 Aalen, AG Ulm HRB 738134 80% Full consolidation *)
Bopfingen MVZ GmbH Hauptstraße 49, 73441 Bopfingen, AG Ulm HRB 738144 80% Full consolidation *)
Dillingen MVZ GmbH Wilhelm-Ködel-Straße 21, 89415 Lauingen (Donau), AG Augsburg HRB 33474 80% Full consolidation *)
Heidenheim MVZ GmbH Bergstraße 7, 89518 Heidenheim an der Brenz, AG Ulm HRB 738265 80% Full consolidation *)
Metzingen MVZ GmbH Christophstraße 2, 72555 Metzingen, AG Stuttgart HRB 768738 80% Full consolidation *)
Reutlingen MVZ GmbH Listplatz 1, 72764 Reutlingen, AG Stuttgart HRB 768807 80% Full consolidation *)
Rottenburg MVZ GmbH Marktplatz 19, 72108 Rottenburg am Neckar, AG Stuttgart HRB 768770 80% Full consolidation *)
Tübingen MVZ GmbH Konrad-Adenauer-Straße 11, 72072 Tübingen, AG Stuttgart HRB 768855 80% Full consolidation *)
Fachärzte für Augenheilkunde ÜBAG GbR Große Allee 37, 89407 Dillingen an der Donau 80% Full consolidation
Südblick GmbH Haagstraße 23, 86316 Friedberg, AG Augsburg HRB 33211 70% Full consolidation *)
Praxisgemeinschaft Dr. Arbunescu-Pecher & Dr. Stephan Maschauer GbR Tegernseer Landstraße 154, 81539 München 50% Equity Method
Ambulantes Operationszentrum Erding GbR Vajuwarenstraße 7, 85435 Erding 14% Equity Method
OculoVision München GmbH Aschauer Straße 30, 81549 München, AG München HRB 178609 60% Full consolidation
Augentagesklinik Zehlendorf MVZ GmbH Clayallee 175, 14195 Berlin, AG Berlin-Charlottenburg HRB 216867 B 80% Full consolidation *)
Wilhelminenhaus Kiel MVZ GmbH Wilhelminenstraße 43, 24103 Kiel, AG Kiel HRB 21411 KI 90% Full consolidation *)
Überörtliche Berufsausübungsgemeinschaft Augenärzte Braunschweig-Göttingen MVZ GmbH Ilka Trinitowski GbR Max-Planck-Weg 7B, 38350 Helmstedt 50% Full consolidation *)
MVZ RHR Augenärzte GmbH Grünstraße 5, 40212 Düsseldorf; AG Düsseldorf HRB 91099 70% Full consolidation *)
Augenzentrum Mühldorf MVZ GmbH Stadtplatz 46, 84453 Mühldorf a. Inn; AG Traunstein HRB 29151 80% Full consolidation *)
Augenklinik Mühldorf GmbH Stadtplatz 46, 84453 Mühldorf a. Inn; AG Traunstein HRB 14986 100% Full consolidation *)
Augenkompetenz Zentrum Bremerhaven MVZ GmbH Grashoffstraße 7, 27570 Bremerhaven; AG Bremen HRB 36516 80% Full consolidation *)
MVZ Auregio GmbH Grafenberger Allee 136, 40237 Düsseldorf; AG Düsseldorf HRB 77465 60% Full consolidation *)
MVZ i-care4u GmbH Kreuzbergstraße 1, 40489 Düsseldorf; AG Düsseldorf HRB 52465 80% Full consolidation *)
Augenklinik Rendsburg GmbH Jungfernstieg 25, 24768 Rendsburg; AG Kiel HRB 960RD 100% Full consolidation *)
Taxi und Transport Neuwerk GmbH Jungfernstieg 25, 24768 Rendsburg, AG Kiel HRB 14346 KI 100% Full consolidation *)
Berolina Augenzentren MVZ GmbH Ferdinandstraße 34, 12209 Berlin; AG Charlottenburg HRB 231005 B 100% Full consolidation *)
Augerlin MVZ GmbH Manfred-von-Richthofen-Straße 8, 12101 Berlin; AG Charlottenburg HRB 197123 B 85% Full consolidation *)
Augenzentrum Oberstenfeld MVZ GmbH Großbottwarer Straße 83, 71720 Oberstenfeld; AG Stuttgart HRB 780587 70% Equity Method
2) Switzerland
Sanoptis AG Zentrum Staldenbach 7, 8808 Pfaeffikon, CHE-216.557.574 100% Full consolidation
Augenzentrum Basel Bahnhof AG Centralbahnstr. 20, 4051 Basel, CHE 331.912.996 70% Full consolidation
Ophthamed AG Centralbahnstr. 20, 4051 Basel, CHE 115.054.873 70% Full consolidation
Eyeparc AG Spitalgasse 26, 3011 Bern, CHE 115.116.310 80% Full consolidation
Berner Augenklinik Group AG Bremgartenstrasse 119, 3012 Bern, CHE 369.468.053 80% Full consolidation
Berner Augenklinik am Lindenhof AG Bremgartenstrasse 119, 3012 Bern, CHE 113.415.167 100% Full consolidation
Dr. J. Menzi Augenarzt AG Bubenbergplatz 8, 3011 Bern; CHE-403.520.539 100% Full consolidation
KammanEye AG Bahnhofstrasse 3, 7270 Davos; CHE-148.782.809 65% Full consolidation
Matia AG Bahnhofstrasse 11, 4242 Laufen; CHE-341.357.783 70% Full consolidation
JuraOphta SA Rue de la Molière 22, 2800 Delémont ; CHE-147.867.455 100% Full consolidation
Augenarzt Schaffhausen AG Fäsenstaubstrasse 39, 8200 Schaffhausen; CHE-164.390.767 51% Full consolidation
OP Zentrum Schaffhausen GmbH Bachstrasse 38, 8200 Schaffhausen; CHE-230.571.337 70% Full consolidation
OphthaVisuell AG Bachstrasse 38, 8200 Schaffhausen; CHE-453.205.896 70% Full consolidation

*) For these companies, the disclosure exemptions according to § 264 para. 3 HGB are applied for.

During the year 2021, the following entities were scoped out of the consolidation:

PG Dr. Kamouna GbR - Dissolution in 2021

nordBLICK Immobilien GmbH - up-stream merger with Sanoptis GmbH in 2021

Ärztezentrum Wilhelminenhaus GmbH - up-stream merger with nordBLICK Augenklinik Bellevue GmbH in 2021

For a list of all companies acquired during the financial year and the respective first consolidation date, we refer you to note 4.2

2.5.1. General

The consolidated accounts include the consolidated balance sheet and the consolidated profit and loss account of the Company and of its subsidiaries, as well as the present accompanying policies.

The accounts of the Group entities have been adjusted, when necessary, in order to comply with the Group's accounting policies.

The profit and loss of the entities acquired in financial year 2021 are included from the first consolidation date to year end.

2.5.2. Consolidation method

Regarding the consolidation method we refer you to note 2.4.

2.5.3. Conversion

The Company and the Group maintains their books and records in EUR.

For presenting consolidated accounts, the assets and liabilities of the Group's foreign operations are expressed in EUR using exchange rates prevailing at the balance sheet date. Income and expense items are translated at the average exchange rates for the period. Exchange differences arising are classified as equity and recognized in the Group's foreign currency translation reserve.

2.5.4. Balances and transactions between consolidated companies

All intercompany balances and intercompany transactions have been eliminated.

2.5.5. Minority interests

The share of the minority interests in the net equity and net profit for the period of the subsidiaries is shown separately in the consolidated balance sheet and profit and loss account, respectively.

2.5.6. Profit and loss account

The figures in the profit and loss account for the acquired companies are reflected on a pro-rata share basis in terms of their acquisition date in order to incorporate only the result since the acquisition date and until the date that control ceases.

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

3.1 Intangible fixed assets

Intangible fixed assets are valued at purchase price including the expenses incidental thereto or at production cost, less accumulated depreciation, amounts written off and value adjustments. Where the Management considers that an intangible fixed asset has suffered a durable depreciation in value, write-down is recorded to reflect this loss. These write-downs are not continued if the reasons for which they were made have ceased to apply. In case of borrowing costs, then these are capitalized to the cost of the asset.

Depreciation charge is as follows:

Denomination Amortization Rate in years Amortization Rate in % Amortization method
Concessions, patents, licenses and trade marks Between 2 and 3 years Between 33,33% to 50% Linear

3.2 Tangible fixed assets

Tangible assets are valued at purchase price including the expenses incidental thereto or at production cost. Tangible fixed assets are depreciated over their estimated useful economic lives.

Where the Management considers that a tangible fixed asset has suffered a durable depreciation in value, write-down is recorded to reflect this loss. These value adjustments are not continued if the reasons for which they were made have ceased to apply. In case of borrowing costs, then these are capitalized to the cost of the asset.

Depreciation charges are as follows:

Denomination Amortization Rate in years Amortization Rate in % Amortization method
Land and buildings Between 10 and 33 years Between 3% to 10% Linear
Plant and Machinery Between 5 and 11 years Between 9% to 20% Linear
Other Fixtures and fittings, tools and equipment Between 1 and 15 years Between 7% to 100% Linear

3.3 Financial Fixed assets

Financial assets are valued at their acquisition cost including the expenses incidental thereto. Value adjustments are made in respect of financial assets to recognize a durable reduction in their value, such reduction being determined and made for each financial asset individually. These value adjustments are not continued if the reasons for which the value adjustments were made have ceased to apply.

3.4 Goodwill

The difference between the acquisition price of the shares in the group entities in the consolidation and their respective adjusted net book value at the date of the acquisition or at the date the group entity is included in the consolidation for the first time, is regarded as goodwill in the absence of identifiable assets or liabilities where this difference could be allocated. This goodwill is amortized on a straight-line basis over 3 to 10 years.

3.5 Stocks

Inventory of goods is valued at the lower of cost using the first in first out ("FIFO") method or market value. Value adjustments are made in respect of inventory when the market value is lower than the purchase price. These value adjustments are not continued if the reasons for which the value adjustments were made have ceased to apply.

3.6 Debtors

Debtors are initially stated at their nominal value. Value adjustments are recorded at the end of the financial year if the net realizable value is lower than their book value. These value adjustments are not continued if the reasons for which the value adjustments were made have ceased to apply.

3.7 Prepayments

This caption includes charges incurred during the financial year but relating to a subsequent financial year.

3.8 Provisions

Provisions are intended to cover losses or debts whose nature is clearly defined and which, at balance sheet date are either likely to be incurred or certain to be incurred but uncertain as to their amount or as to the date on which they will arise.

Provisions may also be created to cover charges which originate in the financial year under review or in a previous financial year, the nature of which is clearly defined and which at the date of the balance sheet are either likely to be incurred or certain to be incurred but uncertain as to their amount or the date on which they will arise.

Provision for dilapidation costs

Due to the fact that most of the buildings used by Sanoptis Group are rented, the management prepared an assessment regarding an eventual provision for dilapidation costs which should be recognized. By considering the general characteristics of a provision as described above, the economical situation and the strategy of Sanoptis Group, the management concluded that, as at 31 December 2021, no provision for dilapidation costs is deemed necessary.

3.9 Creditors

Creditors are stated at their nominal value of repayment.

3.10 Deferred income

This liability item includes income received during the financial year but relating to a subsequent financial year.

3.11 Net Turnover

The net turnover comprises the amount derived from the provision of services falling within the Company's ordinary activities, after deductions of value added tax and other taxes directly linked to the turnover.

3.12 Going concern

The consolidated accounts have been prepared using the going concern principle (see also note 2.3.).

3.13 Deferred tax

Deferred tax liabilities are recognized on temporary differences arising between the tax bases of assets and liabilities and their carrying amount in the annual accounts.

Deferred tax assets are recognized to the extent that is probable that taxable profits will be available against which deductible temporary differences can be utilised and recognized up to the amount of deferred tax liabilities. When appropriate, deferred taxation is provided on losses available for carry forward to offset against taxable profits.

Deferred taxes are measured at tax rates that are expected to apply when the asset is realised or the liability settled, based on tax rates that have been enacted at the date of the balance sheet.

Deferred taxes are recognized in the profit and loss account, except when they relate to items recognized directly in equity, in which case the deferred taxes are also recognized in equity.

NOTE 4 - INTANGIBLE ASSETS

4.1 Concessions, patents and trademark

Concessions, patents and trademarks can be analyzed as follows:

2021 2020
EUR EUR
Gross book value
Opening balance 566.924,60 331.677,36
Fair value of assets acquired as part of business combination 436.671,95 17.587,05
Additions during the period 223.584,78 225.130,99
Disposal during the period (20.239,00) (7.470,80)
Acquisition at cost at the end of the year / period 1.206.942,33 566.924,60
Cumulated Depreciation
Opening balance (202.576,77) (24.692,19)
Depreciation during the period (251.073,84) (185.353,38)
Disposal during the period - 7.468,80
Accumulated value adjustments at the end of the year / period (453.650,61) (202.576,77)
Net book value at the end of the year / period 753.291,72 364.347,83

As at 31 December 2021, the Management of the Group did not consider that any value adjustment was necessary in respect of intangible fixed assets considering that they did not suffer from any durable depreciation in value.

4.3 Goodwill

During the year 2021, the Group acquired the subsidiaries listed below which generated a goodwill amounting to EUR 143.114.221,74. The goodwill will be amortized over 6-10 years on a straight-line basis.

Companies acquired: Registered office Date of 1 st consolidation Companies acquired: Registered office Date of 1 st consolidation
Überörtliche Berufsausübungsgemeinschaft Augenärzte Braunschweig-Göttingen MVZ GmbH Ilka Trinitowski GbR Germany 01/01/2021 Dr. J. Menzi Augenarzt AG Switzerland 01/01/2021
MVZ RHR Augenärzte GmbH Germany 01/01/2021 KammanEye AG Switzerland 01/01/2021
Augenzentrum Mühldorf MVZ GmbH Germany 01/01/2021 Matia AG Switzerland 01/05/2021
Augenklinik Mühldorf GmbH Germany 01/04/2021 JuraOphta SA Switzerland 01/05/2021
Augenkompetenz Zentrum Bremerhaven MVZ GmbH Germany 01/04/2021 Augenarzt Schaffhausen AG Switzerland 01/11/2021
MVZ Auregio GmbH Germany 01/07/2021 OP Zentrum Schaffhausen GmbH Switzerland 01/11/2021
MVZ i-care4u GmbH Germany 01/07/2021 OphthaVisuell AG Switzerland 01/11/2021
Augenklinik Rendsburg GmbH Germany 31/12/2021
Taxi und Transport Neuwerk GmbH Germany 31/12/2021
Berolina Augenzentren MVZ GmbH Germany 01/05/2021
Augerlin MVZ GmbH Germany 01/09/2021

The detail of the goodwill is as follows:

2021 2020
EUR EUR
Gross book value
Opening balance 308.651.019,32 192.574.309,12
Fair value of goodwill following business combination 143.114.221,74 99.083.180,11
Additions following business combination 20.107.257,71 17.116.652,30
Disposal during the period - (304.531,73)
Currency translations adjustments - 181.409,52
Acquisition at the end of the year / period 471.872.498,77 308.651.019,32
Cumulated Depreciation
Opening balance (36.411.447,38) (10.417.382,64)
Amortization of goodwill during period (48.213.618,62) (25.886.632,64)
Disposal during the period - (65.961,45)
Currency translations adjustments 3.395.796,71 (41.470,65)
Accumulated value adjustment at the end of the year / period (81.229.269,29) (36.411.447,38)
Net book value at the end of the year / period 390.643.229,48 272.239.571,94

NOTE 5 - TANGIBLE ASSETS

Tangible assets consist of land and building, plant and machinery and other fixture and fittings which are used by the group and break down as follows:

In EUR (2021) Land and Buildings Plant and Machinery Other fixtures and fittings, tools and equipment Payment on account and tangible assets in the course of construction
Gross book value
Opening balance 3.017.997,46 14.325.696,48 14.526.857,91 943.548,80
Fair value of asset acquired as part of business combination 56.472,54 3.874.715,61 4.934.218,21 80.132,03
Additions during the year 1.098.214,83 8.663.304,85 10.648.499,64 3.732.016,05
Disposal during the year - (518.468,28) (149.602,89) (26.563,00)
Transfers 1.880.410,35 179.278,28 1.078.891,59 (3.088.473,12)
Translation adjustments - - - -
At the end of the year 6.053.095,18 26.524.526,93 31.038.864,46 1.640.660,76
Cumulated Depreciation
Opening balance (790.617,98) (2,302.422,48) (2.371.863,12) -
Depreciation during the year (588.330,88) (3.449.346,39) (4.649.394,56) -
Disposal during the year - 51.739,10 102.888,29 -
Translation adjustments - 6.339,65 (7.054,26) -
At the end of the year (1.348.948,85) (5.693.690,12) (6.925.423,65) -
Net book value at end of the year 4.704.146,33 20.830.836,81 24.113.440,80 1.640.660,76
Net book value at beginning of the year 2.227.379,49 12.023.274,00 12.154.994,79 943.548,80

The building refurbishment and improvement workings at two main locations of the Sanoptis Group lead to higher than usual additions during the year in gross book value.

NOTE 6 - FINANCIAL ASSETS

Movements during the period in financial fixed assets is detailed as follows:

in EUR (2021) Participating interests Investments held as fixed assets Others loans
Gross book value
Opening balance 40,123.58 1,851.51 206,931.76
Fair value of asset acquired as part of business combination 70,000.00 84.41 -
Addition / Disposals during the period (13,984.07) - 222,542.79
At the end of the period 96,139.51 1,935.92 429,474.55
Cumulated Depreciation
Opening balance - - -
Depreciation during the period - - -
At the end of the period - - -
Net Book value at the end of the period 96,139.51 1,935.92 429,474.55
Net book value at beginning of the period 40,123.58 1,851.51 206,931.76

NOTE 7 - CAPITAL AND RESERVES

Movements in the capital and reserves during the period are as follows:

Subscribed capital Share premium account Other non-available reserves Loss carried forward
Balance as at 1 January 2020 27.293.600,00 11.029.831,77 664.578,03 (12.544.663,43)
Share capital increase - - - -
Result allocation - - - (20.897.480,09)
Reserve acquired as part of capital transaction - - - -
Acquired through business combination - - - -
Changes in currency translation adjustment - - (881.675,63) -
Loss for the financial period - - - -
Preferred dividend presented as other liabilities - - - -
Transactions with minority interests - - - -
Capital investment subsidy - - - -
Balance as at 31 December 2021 27.293.600,00 11.029.831,77 -217.097,60 (33.442.143,36)
Loss for the financial period Capital investment subsidy Minority interest TOTAL
Balance as at 1 January 2020 (20.897.480,09) 710.398,63 21.870.783,10 28.127.048,01
Share capital increase - - - -
Result allocation 20.897.480,09 - - -
Reserve acquired as part of capital transaction - - - -
Acquired through business combination - - 29.747.813,49 29.747.813,49
Changes in currency translation adjustment - - - (881.675,63)
Loss for the financial period (39.113.972,75) - 947.968,95 (38.166.003,80)
Preferred dividend presented as other liabilities - - - -
Transactions with minority interests - - (5.766.759,78) (5.766.759,78)
Capital investment subsidy - 309,355,86 - 309.355,86
Balance as at 31 December 2021 (39.113.972,75) 1.019.754,49 46.799.805,76 13.369.778,15

Subscribed Capital

The sole shareholder incorporated the Company with a share capital that initially comprised 12.000 shares divided into 10 classes of shares with the same rights of 1.200 shares each, each share with a nominal value of EUR 1.00, issued and fully paid up for a total of EUR 12.000,00 on 24 September 2018. On 30 April 2019, the sole shareholder resolved to convert the 12.000 shares divided into 10 classes of 1.200 shares into 12.000 ordinary shares with a nominal value of EUR 1.00 each.

During the period ended 31 December 2019, the sole shareholder contributed an aggregate amount of EUR 9.405.008,63 to the share premium of the Company without issuance of shares. In addition, during the same period, minority shareholders have contributed an aggregate amount of EUR 1.624.823,14.

During the financial year ended 31 December 2020, the sole shareholder sold ordinary shares to members of the executive management team. On October 1, 2020, the Company issued 1.600 class 1 and 27.280.000 class 2 preference shares for an amount of respectively EUR 1.600 and EUR 27.280.000, all shares having a nominal amount of EUR 1 and subscribed and paid for by the majority shareholder of the Company. All newly issued shares are pledged in favor of the agent "GlasTrust". A portion of class 1 preference shares and loans payables was subsequently sold to some members of the executive management team.

As at 31 December 2021, the Group has 10 classes of 1.200 ordinary shares each, 1.600 class 1 and 27.280.000 class 2 shares outstanding, each having a nominal value of 1 EUR.

NOTE 8 - CREDITORS

The Group's creditors have the following maturities:

in EUR (2021) Due Within one year Due between one and five years Due after five years Total
Amount owed to credit institutions 5.158.729,82 375.461.217,19 4.746,48 380.624.693,49
Payments received on account of orders in so far as they are not shown separately as deduction from stocks 60.587,54 - - 60.587.54
Trade creditors 14.187.293,82 6.453,83 - 14.193.747,65
Amount owed to affiliated undertakings 2.642.865,58 94.111.339,24 - 96.754.204,82
Other creditors 32.466.981,59 3.289.378,08 - 35.756.359,67
Total 54.516.458,35 472.868.388,34 4.746,48 527.389.593,17
in EUR (2020) Due Within one year Due between one and five years Due after five years Total
Amount owed to credit institutions 2.976.005,87 - 200.184.306,12 203.160.311,99
Payments received on account of orders in so far as they are not shown separately as deduction from stocks - - - -
Trade creditors 9.987.684,20 - - 9.987.684,20
Amount owed to affiliated undertakings 7.939.563,20 - 90.040.390,23 97.979.953,43
Other creditors 10.350.931,69 2.031.470,51 - 12.382.402,20
Total 31.254.184,96 2.031.470,51 290.224.696,35 323.510.351,82

Amount owed to credit institutions

Amounts owed to credit institutions are loans granted by bank to the Company and its subsidiaries on 29 April 2019, allowing for drawdowns in tranches, bearing an interest rate between 5.25 % and 6.25% per annum, and with a maturity of seven years.

In financial year 2021, the following loans excluding arrangement fees were added:

Facilities Borrower Loan Amount Start End
in EUR
Acquisition 4 Sanoptis AG 10.275.237,83 11.01.2021 09.05.2026
Acquisition 4 Sanoptis GmbH 17.031.682,70 11.02.2021 09.05.2026
Acquisition 5 Sanoptis AG 11.482.254,70 28.04.2021 09.05.2026
Acquisition 5 Sanoptis GmbH 31.000.000,00 13.04.2021 09.05.2026
Acquisition 5 Sanoptis GmbH 7.517.745,30 30.06.2021 09.05.2026
Acquisition 6 Sanoptis GmbH 12.850.000,00 30.06.2021 09.05.2026
Acquisition 6 Sanoptis GmbH 15.500.000,00 30.06.2021 09.05.2026
Acquisition 6 Sanoptis GmbH 12.350.000,00 13.09.2021 09.05.2026
Acquisition 6 Sanoptis GmbH 2.675.000,00 02.11.2021 09.05.2026
Acquisition 6 Sanoptis AG 15.046.653,03 03.11.2021 09.05.2026
Acquisition 6 Sanoptis GmbH 578.346,97 12.11.2021 09.05.2026
Acquisition 7 Sanoptis GmbH 1.782.000,00 12.11.2021 09.05.2026
Acquisition 7 Sanoptis GmbH 27.100.000,00 30.12.2021 09.05.2026

As of 31 December 2021, they are composed of EUR 5.158.729,82 owed within one year (2020: EUR 2.976.005,87) and EUR 375.465.963,67 owed between one and five years (2020: EUR 200.184.306,12). The amounts owed to credit institutions concern to the extent of EUR 109.657.773,99 Switzerland (2020: 67.516.902,60) and EUR 270.966.919,50 Germany (2020: 135.643.409,39).

The acquisition facility 7 has a limit of EUR 50,000,000.00 and was only partially utilized with EUR 28,882,000.00 at the end of the financial year 2021.

Amounts owed to affiliated undertakings and Other creditors

As at 31 December 2021, the significant transactions that the Group has with the related parties are as follows:

Amounts owed to other creditors after more than five years and affiliated undertakings after more than five years are composed of an interest-bearing loan, as amended, initially granted by the majority shareholder for EUR 70.000.000,00 with effect as of 24 October 2018. The loan agreement was amended and restated to reflect the entry of the minority shareholders (other creditors) on 1 October 2020 and to increase the total commitment to EUR 500.000.000,00. The loan allows for multiple drawdowns within the limit of EUR 500.000.000,00 and bears interest at a rate being the interest rate received by the Company minus a margin to be kept by the Company as per a transfer pricing analysis. The maturity date of the loan is 24 October 2028.

As of 31 December 2021, the outstanding amounts on the loan are for the minority shareholders EUR 6.647.231 (2020: EUR 2.327.072,13) and EUR 169.490,39 (2020: EUR 145.941,98) as accrued interest; for the majority shareholder EUR 87.448.384 (2020: EUR 87.498.269) and EUR 2.223.010,40 (2020: EUR 2.098.167,66) as accrued interest.

As at 31 December 2021, the Group has no other significant related party transactions except those mentioned previously.

NOTE 9 - NET TURNOVER

Turnover is composed by revenues generated from ophthalmology products and services.

Main variation in turnover is derived from change in scope.

Turnover analyzed by geographic location can be broken down as follows:

in EUR 2021 2020
Germany 163.830.408,28 103.238.892,20
Switzerland 58.295.545,78 31.360.040,45
Net turnover 222.125.954,06 134.598.932,65

NOTE 10 - RAW MATERIALS AND CONSUMABLES AND OTHER EXTERNAL EXPENSES

Main variation in this caption is derived from change in scope.

NOTE 11 - STAFF COSTS

The Group employed an average of 1,840 employees during the financial year 2021 (1,228 for 2020 financial period).

NOTE 12 - TAX ON RESULTS

The tax charge for the year is made up as follows:

in EUR 2021 2020
Current income tax 4,338,613.81 1,497,431.85
Deferred tax expense/(income) 3,110,424.43 (55,848.96)
Total 7,449,038.24 1,441,582.89

NOTE 13 - AUDIT FEES

Fees billed to the Company and its subsidiaries by KPMG Luxembourg, Société cooperative and other member firms of the KPMG network during the year are as follows:

in EUR 2021 2020
Audit fees (annual accounts/consolidated accounts) 509.783,79 443.082,05
Audit-related fees 0,00 0,00
Tax fees 89.126,86 33.206,26
Other fees 5.474,00 9.934,88
Total 604.384,65 486.223,19

Such fees are presented under other external expenses in the consolidated profit and loss account.

NOTE 14 - LEASES

As at 31 December 2021 and 2020 the operational lease agreements are classified below:

in EUR (2021) Note later than one year Later than one year and not later than five years Later than five years
Future minimum lease payments 9,048,056.10 27,477,787.92 30,121,527.27
in EUR (2020) Note later than one year Later than one year and not later than five years Later than five years
Future minimum lease payments 5,535,565.83 15,988,226.59 23,041,501.20

NOTE 15 - CONTINGENCIES AND COMMITMENTS

On 29 April 2019, the Company and some of its subsidiaries entered into a bank facility agreement as borrowers and/or guarantors (see note 8, amounts owed to credit institutions). Fully owned entities of the group, including the Company, pledged the shares they own in subsidiaries, certain receivables and their bank accounts in favor of the agent.

As of 31 December 2021, the country holdings in Germany and Switzerland have drawn down on the facility.

NOTE 16 - ADVANCES AND LOANS GRANTED TO THE MEMBERS OF THE MANAGEMENT AND SUPERVISORY BODIES AND COMMITMENTS ENTERED INTO ON THEIR BEHALF BY WAY OF GUARANTEES OF ANY KIND

There are no advances and loans granted to the members of the management body in that capacity of the Company.

NOTE 17 - SUBSEQUENT EVENTS

The management has carefully assessed the conflict between Russia and the Ukraine with the result that there is neither an impact on the operational nor the financial performance of the Sanoptis Group operating primarily in Switzerland and Germany.

The Company, through subsidiaries, has made 4 new acquisitions, thereof already closed 1, to be financed by existing bank facility. Three acquisitions of the financial year 2021 have been closed in 2022. The bank facility amount has been extended consequently and additional shares pledges made by subsidiaries in favour of the agent.

Subject to the fulfilment of a closing becoming due latest on 1 July 2022, agreements have been signed implying a change of the control at the level of Sanoptis S.à r.l.. .

With this change of control, Sanoptis S.à r.l. will become a subsidiary of Groupe Bruxelles Lambert SA/NV, Brussels.

Nachrichten & Medien

Insolvenzbekanntmachungen

Aktuelle Insolvenzverfahren

Prüfen, ob Insolvenzverfahren für dieses Unternehmen vorliegen

Handelsregister Dokumente

Gesellschafterliste
Aktueller Abdruck
Chronologischer Abdruck

Organisationen an dieser Adresse

99 nahegelegene Organisationen

Liste von Unternehmen und Organisationen an oder in der Nähe dieser Geschäftsadresse. Die Daten umfassen Firmennamen, Adressen, Registrierungsdetails und Branchenklassifikationen.
Die Informationen auf dieser Seite stammen aus öffentlichen Quellen, offiziellen Registern oder werden von Drittanbietern bereitgestellt. Fusionbase übernimmt keine Garantie für die Richtigkeit, Vollständigkeit oder Aktualität der Daten. Melde dich bei Fragen oder Anregungen über unser Kontaktformular.